BTIG Maintains Buy on Glaukos, Raises Price Target to $252
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $234 to $252.
Follow the latest Glaukos Corporation (GKOS) news and market headlines alongside the live GKOS price. Stay informed on what's moving GKOS.
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $234 to $252.
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
AMN Healthcare (AMN) is well-positioned for growth driven by strong healthcare staffing demand, MSP opportunities, and technology investments, with Nurse and Allied revenues rising 27% in Q3. However, the stock faces headwinds from visa delays affecting international nurse placements, pricing pressures, and weakness in Physician and Technology segments. The company holds a Zacks Rank #3 (Hold) rating despite surging 140.5% year-to-date.
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.
Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.
Waters Corporation received FDA 510(k) clearance for its BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test, ready-to-use flow cytometry tests designed to diagnose B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The tests deliver 96.3% sensitivity and 98.2% specificity, reduce manual steps by 95%, and are expected to launch commercially in spring 2027. The stock rose 2.9% following the announcement.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to GKOS, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.